Daraprim: Uses, Side Effects, Dosage & Information

Introduction to Daraprim

Daraprim (pyrimethamine) is a medication primarily used in the treatment of toxoplasmosis, a parasitic infection caused by the protozoan Toxoplasma gondii. It is also sometimes used in combination with other drugs to treat malaria. Daraprim has been at the center of controversy due to a significant price increase in 2015, sparking discussions about drug pricing and access to life-saving medications.

Medical Uses of Daraprim

Toxoplasmosis Treatment

Daraprim is a key component in the treatment of toxoplasmosis, a parasitic infection that can be particularly dangerous for individuals with weakened immune systems, such as those with HIV/AIDS or organ transplant recipients. It is typically used in combination with other medications like sulfadiazine and leucovorin.

Malaria Treatment

In some cases, Daraprim may be prescribed in combination with other antimalarial drugs to treat certain types of malaria, especially for patients who cannot tolerate or do not respond to first-line treatments.

Use with Leucovorin

Leucovorin (folinic acid) is often given alongside Daraprim to help counteract the potential side effects of folic acid deficiency caused by pyrimethamine.

Mechanism of Action

Pyrimethamine: The active ingredient in Daraprim

The active ingredient in Daraprim is pyrimethamine, a folic acid antagonist that inhibits the enzyme dihydrofolate reductase (DHFR). This enzyme is crucial for the synthesis of purines and pyrimidines, which are essential for DNA synthesis and cell replication.

Combination with Sulfonamides

Pyrimethamine is often used in combination with sulfonamides, such as sulfadiazine, to achieve a synergistic effect against the parasite. Sulfonamides also inhibit folate synthesis, complementing the action of pyrimethamine and enhancing the overall efficacy of the treatment.

Source: Pyrimethamine – StatPearls – NCBI Bookshelf

Daraprim‘s Drug Profile

Form and Dosage: Tablet form, 25 mg

Daraprim is available in the form of scored, round tablets containing 25 mg of pyrimethamine. The typical adult dosage for the treatment of toxoplasmosis is 25-75 mg daily, depending on the patient’s condition and response to therapy.

Administration Guidelines

Daraprim should be taken orally with food or a glass of milk to improve absorption. Patients should follow the dosage instructions provided by their healthcare provider and not change or discontinue the medication without consulting them.

Source: Pyrimethamine: MedlinePlus Drug Information

Side Effects and Interactions

Common Side Effects

The most common side effects associated with Daraprim include nausea, vomiting, rash, anemia, and potential bone marrow suppression. It can also cause folic acid deficiency, which is why leucovorin is often prescribed alongside it.

Potential Drug Interactions

Daraprim may interact with certain medications, including anticonvulsants, zidovudine (AZT), and medications that can cause bone marrow suppression. It is essential to inform the healthcare provider about all medications, vitamins, and supplements being taken.

Safety Profile

Daraprim should be used with caution in patients with kidney or liver disease, as well as in pregnant or breastfeeding women. Dosage adjustments may be necessary for these populations.

Source: Daraprim (pyrimethamine) Label

History of Daraprim

Introduction and Approval

Daraprim (pyrimethamine) was first introduced in 1953 and approved by the U.S. Food and Drug Administration (FDA) for the treatment of toxoplasmosis, malaria, and certain types of pneumocystis pneumonia.

Patent Status and Off- Patent Transition

The original patent for Daraprim expired in the 1960s, and the drug was marketed by various pharmaceutical companies as a generic medication for several decades. In 2015, Turing Pharmaceuticals acquired the rights to Daraprim and raised the price significantly, leading to widespread controversy.

Source: The Daraprim Price Increase: A Case Study in How Life-Saving Drugs Become Unaffordable

Price Controversy

Price Increase Incident: From $13.50 to $750 per tablet

In 2015, Turing Pharmaceuticals, led by former CEO Martin Shkreli, acquired the rights to Daraprim and raised the price from $13.50 to $750 per tablet, an increase of over 5,000%.

Public and Legal Reactions

The dramatic price hike sparked widespread outrage from patients, healthcare providers, and the public, leading to investigations by the U.S. Congress and various state attorneys general. Shkreli faced criminal charges and was eventually convicted of securities fraud.

Impact on Patients and Healthcare

The price increase made Daraprim essentially unaffordable for many patients, particularly those without adequate insurance coverage or financial resources. This situation highlighted concerns about drug pricing practices and their potential impact on patient access to life-saving medications.

Source: Drug-Pricing Debate Rekindles After Hike for Decades-Old Drug

Legal and Regulatory Actions

Martin Shkreli’s Role and Legal Consequences

Martin Shkreli, the former CEO of Turing Pharmaceuticals, was at the center of the Daraprim price controversy. He was eventually convicted of securities fraud charges unrelated to the Daraprim case but was ordered to return the profits from the price hike.

Court Orders and Financial Penalties

In 2022, a federal judge ordered Shkreli to pay $64.6 million in profits from the Daraprim price increase, which will be distributed to those affected by the price hike.

Source: Judge Orders Martin Shkreli to Return $64 Million in Profits From Daraprim

Alternatives to Daraprim

While Daraprim is a critical component in the treatment of toxoplasmosis, alternative medications and combination therapies are available. These include other antiparasitic drugs like trimethoprim-sulfamethoxazole, clindamycin, and atovaquone, which may be used depending on the patient’s condition and the specific strain of the parasite.

Source: Treatment of Toxoplasmosis – CDC

Generic Daraprim

FDA Approval of First Generic Version

In 2020, the FDA approved the first generic version of Daraprim (pyrimethamine), paving the way for increased competition and potentially lower prices for patients.

Implications for Accessibility and Pricing

The introduction of generic versions of Daraprim is expected to improve patient access to this life-saving medication and help address the pricing concerns raised during the controversy.

Source: infection” target=”_blank” rel=”noopener noreferrer”>FDA Approves First Generic Versions of Drug Used to Treat Toxoplasmosis Parasitic Infection

Distribution Program

DARAPRIM® Direct for Patients

Turing Pharmaceuticals (now Vyera Pharmaceuticals) established a distribution program called DARAPRIM® Direct to help patients access the medication. This program aims to provide Daraprim at an affordable cost for certain eligible patients.

How Patients Can Access Daraprim

Patients can work with their healthcare providers and specialty pharmacies to enroll in the DARAPRIM® Direct program and potentially receive the medication at a reduced cost based on their financial situation and insurance coverage.

Source: DARAPRIM® Direct

Research and Development

While Daraprim has been on the market for decades, ongoing research continues to explore its potential applications and optimize its use in combination with other therapies. Clinical trials and studies aim to improve treatment protocols, understand drug interactions, and address potential resistance mechanisms.

Source: Pyrimethamine – Therapeutic Applications and Challenges

Global Impact

Use in Tropical Regions

Daraprim and its generic versions play a crucial role in the treatment of toxoplasmosis and certain types of malaria in tropical and subtropical regions where these diseases are more prevalent.

Public Health Perspectives

The availability and affordability of Daraprim have significant public health implications, particularly in resource-limited settings. Efforts are ongoing to ensure equitable access to this life-saving medication globally.

Source: The Global Challenge of Toxoplasmosis: Current Knowledge and Future Directions